{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:34:41Z","timestamp":1790696081360,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DDX41 mutations (germline and somatic) are associated with late onset myelodysplastic syndromes\/acute myeloid leukemia (MDS\/AML). Myeloid neoplasms (MN) with germline predisposition was identified as a distinct category in the 2016 WHO classification revision, including MN with germline DDX41 mutation. We retrospectively analyzed the molecular findings and clinical characteristics of thirty-three DDX41-mutated (mDDX41) patients at our institution. We identified 14 distinct pathogenic DDX41 variants in 32 patients and 8 DDX41 variants of unknown significance (VUS) in 9 patients. Five (16%) patients had a second DDX41 somatic mutation p.R525H and 13 (40%) had at least one additional oncogenic co-mutation in other genes. The median age at the time of diagnosis was 66 years, with male predominance (72%) and the majority of patients had normal cytogenetics (91%). Two-year overall survival (OS) was 86% and 6 (21%) MDS\/AML patients with relatively preserved hematopoietic function were observed without further intervention. In comparison to AML patients with prognostically more favorable subtypes [t(8;21), n=27 and inv(16), n=40], mDDX41 patients in our cohort showed similarly favorable OS. Our study highlights that mDDX41-MN patients often have an indolent course and mDDX41-AML has comparable OS to favorable-risk AML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005738","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T02:21:38Z","timestamp":1634523698000},"page":"528-532","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Genetic features and clinical outcomes of patients with isolated and comutated\n                    <i>DDX41<\/i>\n                    -mutated myeloid neoplasms"],"prefix":"10.1182","volume":"6","author":[{"given":"Hassan B.","family":"Alkhateeb","sequence":"first","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5065","authenticated-orcid":false,"given":"Ahmad","family":"Nanaa","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viswanatha","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sproat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad E.","family":"Salama","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"Division of Cytogenetics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun Vinod","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"2","key":"2022011916244019100_B1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-017-2260-y","article-title":"Myeloid neoplasms with germline DDX41 mutation","volume":"106","author":"Cheah","year":"2017","journal-title":"Int J Hematol."},{"issue":"2","key":"2022011916244019100_B2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.seminhematol.2017.04.007","article-title":"DDX41-related myeloid neoplasia","volume":"54","author":"Maciejewski","year":"2017","journal-title":"Semin Hematol."},{"issue":"10","key":"2022011916244019100_B3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ni.2091","article-title":"The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells [correction published in Nat Immunol. 2012;13:196]","volume":"12","author":"Zhang","year":"2011","journal-title":"Nat Immunol."},{"issue":"7","key":"2022011916244019100_B4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2017-09-806489","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood."},{"issue":"2","key":"2022011916244019100_B5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13317","article-title":"Haematopoietic and immune defects associated with GATA2 mutation","volume":"169","author":"Collin","year":"2015","journal-title":"Br J Haematol."},{"issue":"2","key":"2022011916244019100_B6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv."},{"issue":"10","key":"2022011916244019100_B7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat Genet."},{"issue":"8","key":"2022011916244019100_B8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","article-title":"Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies","volume":"127","author":"Lewinsohn","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022011916244019100_B9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2007.06909.x","article-title":"Familial myelodysplasia and acute myeloid leukaemia: a review","volume":"140","author":"Owen","year":"2008","journal-title":"Br J Haematol."},{"issue":"5","key":"2022011916244019100_B10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell."},{"issue":"7","key":"2022011916244019100_B11","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia."},{"issue":"2","key":"2022011916244019100_B12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat Genet."},{"issue":"6","key":"2022011916244019100_B13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11899-018-0473-7","article-title":"Hereditary myelodysplastic syndrome and acute myeloid leukemia: diagnosis, questions, and controversies","volume":"13","author":"Akpan","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"key":"2022011916244019100_B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-140174","article-title":"Clinical impacts of germline DDX41 mutations on myeloid neoplasms","volume":"136","author":"Makishima","year":"2020","journal-title":"Blood."},{"issue":"7","key":"2022011916244019100_B15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","article-title":"DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease","volume":"94","author":"Quesada","year":"2019","journal-title":"Am J Hematol."},{"issue":"17","key":"2022011916244019100_B16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"S\u00e9bert","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2022011916244019100_B17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.25610","article-title":"Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation","volume":"95","author":"Abou Dalle","year":"2020","journal-title":"Am J Hematol."},{"issue":"12","key":"2022011916244019100_B18","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/leu.2016.228","article-title":"Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide","volume":"30","author":"Negoro","year":"2016","journal-title":"Leukemia."},{"issue":"6","key":"2022011916244019100_B19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.16668","article-title":"Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations","volume":"192","author":"Qu","year":"2021","journal-title":"Br J Haematol."},{"key":"2022011916244019100_B20","doi-asserted-by":"crossref","first-page":"582213","DOI":"10.3389\/fonc.2020.582213","article-title":"Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations","volume":"10","author":"Bannon","year":"2021","journal-title":"Front Oncol."},{"issue":"12","key":"2022011916244019100_B21","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022011916244019100_B22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2002-11-3527","article-title":"Prognosis of inv(16)\/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup","volume":"102","author":"Delaunay","year":"2003","journal-title":"Blood."},{"issue":"4","key":"2022011916244019100_B23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/528\/1860714\/advancesadv2021005738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/528\/1860714\/advancesadv2021005738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:14:27Z","timestamp":1699676067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/2\/528\/477281\/Genetic-features-and-clinical-outcomes-of-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005738","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}